Featured
Wellthy Therapeutics
Wellthy Therapeutics is a Cardiometabolic InsurTech company that uses a Human – Artificial Intelligence (AI) hybrid along with proven behaviour change models to improve policyholder and patient health outcomes in Asia. It develops and deploys InsurTech solutions that work synergistically with insurers to improve health, quality of life, and enable better outcomes. Live now with a few health and life insurers in India, its digital therapeutic solution has shown proven ability to significantly reduce risk. One such pilot with South Asia’s largest private health insurer is already complete, with the results being presented at the world’s largest diabetes conference later this year.
Wellthy Therapeutics develops new policies that can go to market across Asia for prevention and reduction of cardiovascular and chronic disease risk, to engage and reduce the risk of the in-force book, and to enable ‘risky’ rejected customers to come back into the insurable risk pool.
It’s first digital therapeutic for type II diabetes is already prescribed by doctors to patients in India, and its second digital therapeutic in chronic kidney disease is leading South Asia’s largest dialysis prevention program. Going forward, Wellthy Therapeutics will be working to cover more diseases across the cardio metabolic spectrum, while launching in select Asian markets with our insurance and hospital system partners.
Wellthy has a proven track record of clinical efficacy, with outcomes data presented at conferences by the American Diabetes Association (ADA), International Diabetes Federation (IDF), American Association for Clinical Endocrinology (AACE), Advanced Technologies & Treatments in Diabetes (ATTD) and the Research Society for Study of Diabetes in India (RSSDI).
Wellthy has raised a seed round of $2M in 2018 from from marquee investors who brought expertise in both healthcare and technology. GrowX ventures was the first investor to come on board. Other investors include strategists like Dr. Ranjan Pai, Manipal Group, Beenext Ventures, Currae Healthcare and others.
Products
Wellthy Care
Cardio Metabolic Risk Management
Modules:
- Healthy coping
- Medication Adherence
- Healthy eating
- Being Active
- Reducing weight
- Diagnostic adherence
- Kidney function testing
- Blood pressure monitoring
- Lipid monitoring
- SMBG adherence
News & Events
Digital therapeutics firm Wellthy Therapeutics raises Rs 13.5 Cr funding
05/03/2018
Digital therapeutics firm Wellthy Therapeutics has raised Rs 13.5 crore ($2.1 million) from Ranjan Pai’s family office Manipal Education & Medical Group (MEMG) family office LLP along with Apoorva Patni-led Currae Healthtech Fund, Singapore-based Beenext Ventures, GrowX Ventures, IIFL Select Equity Fund amongst other individual investors.
The Mumbai-based firm that plays into digital therapeutics, enables treatment of type-II diabetes using a hybrid of AI and human paramedical coaches to improve health literacy and facilitate behaviour change for better outcomes in patients.
The Mumbai-based firm that plays into digital therapeutics, enables treatment of type-II diabetes using a hybrid of AI and human paramedical coaches to improve health literacy and facilitate behaviour change for better outcomes in patients.
Wellthy Therapeutics: Taming diabetes
18/09/2017
The app has been endorsed by some major organisations. In 2016, Wellthy partnered with the New Delhi-based Research Society for the Study of Diabetes in India (RSSDI) to become an application that doctors could prescribe to their patients. At an American Diabetes Association conference, Wellthy presented the results of a clinical trial that established itself as the first South Asian digital therapeutics company to publish positive clinical outcomes.
The issue, says Shah, highlights the challenge of behavioural change, which is a prerequisite to eating healthier, exercising and taking pills consistently. “What I realised is that every business is about behavioural change,” he says. “For example, telling someone not to hail a cab and to instead press a button on the phone requires a huge behavioural change. I was amazed to see that despite incredible advances happening in consumerism through behavioural change, nobody was applying the same experience to health care.”
The world of health care, specifically with regard to chronic diseases like type 2 diabetes, is perhaps the perfect ecosystem for the application of the behavioural change model. In the case of diabetes, the effects of a behavioural change can be precisely quantified through the glycated haemoglobin (HbA1c) test.
“The genetic makeup of Asians is different, our behaviour and values are different, our cultural nuances are different,” explains Shah.
So, Wellthy made a conscious decision to focus its efforts on Asians. This is a wise business move given that two-thirds of the world’s diabetics live in Asia, according to WHO data.
The issue, says Shah, highlights the challenge of behavioural change, which is a prerequisite to eating healthier, exercising and taking pills consistently. “What I realised is that every business is about behavioural change,” he says. “For example, telling someone not to hail a cab and to instead press a button on the phone requires a huge behavioural change. I was amazed to see that despite incredible advances happening in consumerism through behavioural change, nobody was applying the same experience to health care.”
The world of health care, specifically with regard to chronic diseases like type 2 diabetes, is perhaps the perfect ecosystem for the application of the behavioural change model. In the case of diabetes, the effects of a behavioural change can be precisely quantified through the glycated haemoglobin (HbA1c) test.
“The genetic makeup of Asians is different, our behaviour and values are different, our cultural nuances are different,” explains Shah.
So, Wellthy made a conscious decision to focus its efforts on Asians. This is a wise business move given that two-thirds of the world’s diabetics live in Asia, according to WHO data.
Swiss Re & Wellthy Therapeutics partner to improve access to diabetes insurance
10/08/2017
Reinsurance giant Swiss Re is to partner with Indian digital therapeutics firm, Wellthy Therapeutics, in order to develop more accessible, affordable and effective insurance solutions for people with Type 2 Diabetes.
Wellthy Therapeutics is one of five companies selected as part of Swiss Re’s InsurTech Accelerator programme
The collaboration aims to develop new solutions for people in India with Type 2 Diabetes, and will see Wellthy’s artificial intelligence (AI) powered mobile intervention tool, which the firm says focuses on “reversing and controlling diabetes through integrated care,” with Swiss Re’s global insurance and reinsurance industry expertise to create “clinically validated digital health solutions for health and life-insurers.”
Kalpana Sampat, Chief Executive Officer (CEO) of Swiss Re’s India division, said; “Chronic diseases like diabetes are a massive risk factor for various complications that lead to hospitalization, disability and reduced longevity. We are constantly working to empower our clients and their policyholders with the tools to live happier, healthier and longer lives.
“We are excited to work with Wellthy Therapeutics to facilitate prevention, control and reversal of policyholder chronic conditions like diabetes through their clinically validated intervention, and explore ways to provide this tool to our clients to achieve a common goal.”
Wellthy’s AI platform offers an integrated care platform for managing and reversing diabetes, which the firm says has positive side effects, such as improved weight management, increased physical activity, and an overall better quality of life.
Wellthy Therapeutics is one of five companies selected as part of Swiss Re’s InsurTech Accelerator programme
The collaboration aims to develop new solutions for people in India with Type 2 Diabetes, and will see Wellthy’s artificial intelligence (AI) powered mobile intervention tool, which the firm says focuses on “reversing and controlling diabetes through integrated care,” with Swiss Re’s global insurance and reinsurance industry expertise to create “clinically validated digital health solutions for health and life-insurers.”
Kalpana Sampat, Chief Executive Officer (CEO) of Swiss Re’s India division, said; “Chronic diseases like diabetes are a massive risk factor for various complications that lead to hospitalization, disability and reduced longevity. We are constantly working to empower our clients and their policyholders with the tools to live happier, healthier and longer lives.
“We are excited to work with Wellthy Therapeutics to facilitate prevention, control and reversal of policyholder chronic conditions like diabetes through their clinically validated intervention, and explore ways to provide this tool to our clients to achieve a common goal.”
Wellthy’s AI platform offers an integrated care platform for managing and reversing diabetes, which the firm says has positive side effects, such as improved weight management, increased physical activity, and an overall better quality of life.
Diabetes Care goes digital as RSSDI partners with Wellthy Therapeutics
21/12/2016
The Research Society for The Study of Diabetic in India (RSSDI) has partnered with Wellthy Therapeutics, a digital therapeutics company focused on improving diabetes care and outcomes through Artificial Intelligence. Wellthy Diabetes is an artificial intelligence powered diabetes health coach for patients and a virtual clinical assistant for doctors.
This is a first of its kind RSSDI endorsement for an application that can be prescribed by doctors to patients. The partnership was announced at the recently concluded annual RSSDI conference held in Hyderabad.
This is a first of its kind RSSDI endorsement for an application that can be prescribed by doctors to patients. The partnership was announced at the recently concluded annual RSSDI conference held in Hyderabad.
Our Case Studies and Whitepapers
Whitepaper - Pattern of protein consumption in major meals by patients with type-2 diabetes in India
Aim: To qualitatively understand the pattern of protein consumption in major meals i.e. Breakfast, Lunch and Dinner in real world settings in order to influence improved glycemic control through real-time feedback and coaching.
Results: Sixty-three participants (77% vegetarian, n=49/63) reported a total 2174 meals including 773, 760 and 614 instances of breakfast, lunch, and dinner respectively. Of the reported meals, nutritionists graded 41% (n=895) of meal instances as missing a source of protein. 53% of breakfasts, 31% lunch and 38% dinner were found to be without any source of protein. The percentage of meals missing a source of protein for Vegetarians compared to Non-Vegetarians was 60% vs 48% for breakfast, 28% vs 33% for lunch and 41% vs 28% for dinner instances. Only 21% of breakfast, 23% of lunch and 27% of dinner meals were identified to include first-class proteins.
Conclusion: From this study, we observe that majority instances of meals, and breakfasts, in particular, consumed by patients with type-2 diabetes in India lack presence of a source of protein. Increasing protein in meals is necessary to manage postprandial glycemia. Real-time feedback on the protein content of meals with continuous coaching to increase it will be essential for the successful achievement of blood sugar targets and improved clinical outcomes in patients with type-2 diabetes.
Results: Sixty-three participants (77% vegetarian, n=49/63) reported a total 2174 meals including 773, 760 and 614 instances of breakfast, lunch, and dinner respectively. Of the reported meals, nutritionists graded 41% (n=895) of meal instances as missing a source of protein. 53% of breakfasts, 31% lunch and 38% dinner were found to be without any source of protein. The percentage of meals missing a source of protein for Vegetarians compared to Non-Vegetarians was 60% vs 48% for breakfast, 28% vs 33% for lunch and 41% vs 28% for dinner instances. Only 21% of breakfast, 23% of lunch and 27% of dinner meals were identified to include first-class proteins.
Conclusion: From this study, we observe that majority instances of meals, and breakfasts, in particular, consumed by patients with type-2 diabetes in India lack presence of a source of protein. Increasing protein in meals is necessary to manage postprandial glycemia. Real-time feedback on the protein content of meals with continuous coaching to increase it will be essential for the successful achievement of blood sugar targets and improved clinical outcomes in patients with type-2 diabetes.
Whitepaper - Evidence of an artificial intelligence tool to augment data driven decisions for diabetes care in developing countries
BACKGROUND & AIM: The lack of real world data on clinical trends, lifestyle, and the patient journey between consultations severely limits physicians on their ability to deliver evidence-backed personalized care for subjects with type 2 diabetes (T2DM) in developing countries.
This study aims to demonstrate the potential of a digital therapeutic, Wellthy Diabetes, delivered through a smartphone app, to engage patients to self-report lifestyle and clinical data in a low literacy and low health engagement setting like India. The objective is to capture relevant clinical and lifestyle data that can be made available to treating physicians and allied health professionals at the moment of care to enable augmented data-driven clinical decisions and better personalization of care without having health professionals make any additional investment in time, people or physical infrastructure.
A total of 11,739 diabetes related clinical and lifestyle data points were captured from 64 patients over 2641 person days of usage of WD App. The mean duration of a subject on the app was 41.2 days during which on average 183 clinical and lifestyle data points were tracked per user at a mean velocity of 4.7 data points per user per day. The mean FBS and PBS readings were 136 mg/dl [CI: 102-172] and 180 mg/dl [CI:115 - 234]. A total of 302 weight readings were reported at an average of 4.95 weight readings per user. Further, a of total of 59,859 minutes of physical activity were tracked using in-built sensors on the smartphone and self reported by users. On average 120 instances of activity were tracked per user.
This study aims to demonstrate the potential of a digital therapeutic, Wellthy Diabetes, delivered through a smartphone app, to engage patients to self-report lifestyle and clinical data in a low literacy and low health engagement setting like India. The objective is to capture relevant clinical and lifestyle data that can be made available to treating physicians and allied health professionals at the moment of care to enable augmented data-driven clinical decisions and better personalization of care without having health professionals make any additional investment in time, people or physical infrastructure.
A total of 11,739 diabetes related clinical and lifestyle data points were captured from 64 patients over 2641 person days of usage of WD App. The mean duration of a subject on the app was 41.2 days during which on average 183 clinical and lifestyle data points were tracked per user at a mean velocity of 4.7 data points per user per day. The mean FBS and PBS readings were 136 mg/dl [CI: 102-172] and 180 mg/dl [CI:115 - 234]. A total of 302 weight readings were reported at an average of 4.95 weight readings per user. Further, a of total of 59,859 minutes of physical activity were tracked using in-built sensors on the smartphone and self reported by users. On average 120 instances of activity were tracked per user.
Whitepaper - EFFECTIVENESS OF A DIGITAL THERAPEUTIC FOR IMPROVING OUTCOMES IN SOUTH ASIANS LIVING WITH TYPE-2 DIABETES
Health Insurers in South Asia are challenged by lack of a clinically effective lifestyle intervention that can be delivered at scale to their insured populations. This study reports results for a subset of partici- pants (who completed the intervention at the time of submitting this abstract) of a real-world pilot of Wellthy DiabetesTM (WD), a digital therapeutic for people living with type-2 diabetes, in collaboration with an insurance provider with the aim to validate WD as a diabetes management and risk reduction tool.
For the 39 participants (mean age: 50.5 yrs & 62% males) mean pre and post-intervention A1c were 8.31% (95%CI:7.85-8.78) and 7.7% (95%CI: 7.28-8.12) respectively. A mean reduction of 0.61% A1c (95%CI:0.26-0.96, p=0.001) was reported post inter- vention with 62% (n=24) of participants reducing A1c with a mean change of -1.17% A1c (95% CI: 0.75-1.60).
This study demonstrates Wellthy Diabetes as a clinically effective intervention for health insurers in South Asia to improve health outcomes and reduce risk for people with type-2 diabetes.
For the 39 participants (mean age: 50.5 yrs & 62% males) mean pre and post-intervention A1c were 8.31% (95%CI:7.85-8.78) and 7.7% (95%CI: 7.28-8.12) respectively. A mean reduction of 0.61% A1c (95%CI:0.26-0.96, p=0.001) was reported post inter- vention with 62% (n=24) of participants reducing A1c with a mean change of -1.17% A1c (95% CI: 0.75-1.60).
This study demonstrates Wellthy Diabetes as a clinically effective intervention for health insurers in South Asia to improve health outcomes and reduce risk for people with type-2 diabetes.
